ArticleAmerican journal of nuclear medicine and molecular imaging2013
Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity.
Article in American journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Hypoxia: The Cornerstone of Glioblastoma.International journal of molecular sciences · 2021Review
- Article
- Target selection of CAR T cell therapy in accordance with the TME for solid tumors.American journal of cancer research · 2019Review
- PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Article
- Biomarkers in preclinical cancer imaging.European journal of nuclear medicine and molecular imaging · 2015Review
- OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model.American journal of nuclear medicine and molecular imaging · 2015Article
- VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo.Biomaterials · 2015Article
- Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with (64)Cu-NOTA-TRC105.American journal of translational research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-invasive and quantitative imaging of vascular endothelial growth factor receptor-2 (VEGFR-2) expression levels is highly important in cancer diagnosis, prognosis, and patient management. Although various literature reports have investigated the tumor expression levels of VEGFR-2 using imaging techniques such as positron emission tomography, single-photon emission computed tomography, targeted ultrasound, etc., accurate evaluation of the dynamic microdistribution of VEGFR-2 in vivo with good spatial and temporal resolution remains a major challenge. In this issue of the American Journal of Nuclear Medicine and Molecular Imaging, He at al. reported the use of a VEGFR-2 targeted probe for magnetic resonance imaging (MRI) of VEGFR-2 in two glioma models in rats (i.e. C6 and RG2). The heterogeneity of VEGFR-2 expression was non-invasively imaged with MRI and validated with various in vitro, in vivo, and ex vivo experiments. Not only was heterogeneous expression of VEGFR-2 found in different glioma tumors, it was also observed in different regions within the same tumor (e.g. tumor periphery, peri-necrotic area, and tumor interior). This report highlights the complex nature of gliomas, which may offer invaluable insights into tumor heterogeneity and potential clinical management of glioma patients. These patients have dismal clinical outcomes and are in urgent need of better tools to improve brain tumor treatment.
Indexed as
Identifiers
23900733PMC3715775W2191601305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.